{"id":"W6976952699","doi":"10.6084/m9.figshare.23505264.v1","title":"Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Everolimus; Metastatic breast cancer; Breast cancer; Phases of clinical research; Placebo; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003109993,0.00134544,0.002007212,0.000836728,0.0007126749,0.001282959,0.001436746,0.001468769,0.8626561],"category_scores_gemma":[0.02237315,0.0008390525,0.001243776,0.001551625,0.0003592596,0.001201429,0.0006121825,0.001274272,0.08161492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121515,"about_ca_system_score_gemma":0.002201472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00190341,"about_ca_topic_score_gemma":0.004468866,"domain_scores_codex":[0.9989105,0.0004276893,0.0001823997,0.0001823075,0.0001622994,0.0001346703],"domain_scores_gemma":[0.980493,0.014555,0.001982389,0.0008621218,0.001363865,0.0007435977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02339021,0.0009073491,0.001118931,0.01541546,0.0004814673,0.0001111137,0.00005636812,0.001144657,0.0003906895,0.002004867,0.9237036,0.03127513],"study_design_scores_gemma":[0.3905739,0.00751356,0.01929203,0.005673297,0.001811586,0.0006818189,0.0001121587,0.002708351,0.001697887,0.01598481,0.5537583,0.0001922687],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"dataset","genre_gemma":"dataset","genre_scores_codex":[0.0009094284,0.000244349,0.0006777206,0.0005221333,0.0001232969,0.002619452,0.9905199,0.0004761468,0.003907524],"genre_scores_gemma":[0.05231833,0.001664317,0.01471692,0.004210026,0.0008391392,0.0601458,0.8119047,0.001168647,0.05303211],"genre_candidate":"dataset","genre_consensus":"dataset","teacher_disagreement_score":0.8626561,"threshold_uncertainty_score":0.1959045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03896974722991319,"score_gpt":0.3260091082391712,"score_spread":0.287039361009258,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}